Elevance Health UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome, everyone, to the third and final day of our conference. We appreciate your being here. We particularly appreciate Elevance Health being part of the conference this morning and kicking us off on Wednesday. We have Mark Kaye, Executive Vice President, Chief Financial Officer. We also have Nathan Rich, Head of Investor Relations, with us here. Thanks so much, guys, for doing this again. Mark, maybe a big-picture question. Stepping back from the individual businesses, what are the two or three strategic choices that will matter most for Elevance over the next three years? How should investors distinguish the earnings recovery that seems to be underway from the actions designed to establish a stronger, more durable long-term growth model for the company? What milestones would tell us that the strategy's on track?
AJ, thank you so much to yourself and UBS for hosting. It's a pleasure to be here today. I think it's a great place to begin our discussion. In the near term, our priorities are focused on strengthening earnings and building a foundation for future growth. Those efforts are connected by a common strategy: lowering the cost of healthcare and making the experience simpler and better for members. First, we're restoring sustainable margins in health benefits. That means maintaining discipline in pricing and portfolio decisions while advancing medical cost management. Better alignment between revenue and costs support the recovery while improving the underlying cost of care that helps make the progress much more durable.
Second, we're scaling Carelon's pharmacy and clinical capabilities across our health plans and with external clients. That includes expanding risk-based solutions in complex, high-cost areas like oncology, behavioral health, and care in the home. Our differentiation really comes from how those capabilities work together. For example, dual-eligible members, we are able to pair attractive plan designs with coordinated pharmacy and clinical support, including care in the home. That helps us address members' needs more effectively while reducing avoidable costs. As we demonstrate that value within our health plans, we strengthen health benefits and build the evidence and operating experience to expand with external customers. That gives us a growth opportunity beyond health plan members alone. Third, we're making our operating model more connected and scalable. Data and AI have helped us identify member needs earlier and to translate those insights into timely support.
They also help simplify interactions with providers and reduce manual work. The opportunity is to deliver a more personalized experience while serving more members and clients efficiently. Taken alongside disciplined capital deployment, those actions can help us achieve a solid baseline from which we can achieve our long-term EPS growth objectives.
Okay. Then within your framework for at least 12% adjusted EPS growth in 2027 from the recently increased 2026 earnings baseline, what drivers have the greatest visibility today, and which remain more dependent on external conditions? How much of the improvement reflects margin normalization versus history versus repeatable organic earnings growth?
We remain confident in delivering at least 12% adjusted EPS growth in 2027 from our higher 2026 earnings baseline of at least $26.75. That baseline reflects stronger underlying performance this year, and it does exclude non-recurring items. In Medicare Advantage, our deliberate portfolio actions are already translating into stronger performance. Our 2027 bids build on that progress, and they are designed to support further margin improvement and targeted growth, particularly in duals. Importantly, those bids assume a similar level of medical cost trend to 2026. In Medicaid, we expect better rate alignment and a growing contribution from our medical cost actions to support margin improvement. The pace of that improvement is partly dependent on state actions, including the timing and adequacy of rate updates and the implementation of community engagement requirements.
In commercial and individual ACA, our 2027 pricing reflects our forward view of medical costs and the populations that we continue to serve. Alongside that pricing discipline, our commercial fee-based business provides an additional source of growth supported by a very strong national account selling season. Finally, in Carelon, here we add a repeatable organic growth opportunity through a broader adoption of our risk-based clinical programs and deeper pharmacy relationships with employers. We expect that expansion, both internally and externally, to more than offset the affiliated pressure from lower health plan or anticipated affiliated health plan membership. Finally, I would say that the distinction here is that margin recovery strengthens our current earnings base, while client growth and broader adoption of our capabilities expand that base over time.
Both obviously contribute to our 2027 framework, and it is that breadth, not the dependence on any single business or assumption, is what supports our outlook for 2027.
Okay, great. As you think about allocating resources across health benefits and Carelon, where do you see the strongest risk-adjusted returns over the next three years? To the extent M&A can supplement growth, where might the company look, and what is your appetite for assets like we've seen in the market recently, surgery centers, infusion services, and physician groups?
That's a great question. Some of our most attractive risk-adjusted returns come from scaling capabilities we already own across established member and client relationships. We can extend a proven solution without having to build a new business or a customer base from the ground up. That is why integration has been a priority for us this year. We're focused on realizing the value of our acquisitions and establishing the operating capacity to support further growth. As that work progresses, we expect to evaluate selective M&A more actively in 2027 and beyond. Within Carelon, our priorities include capabilities that strengthen the management of complex and chronic conditions, expand our ability to take risk in high-cost care, and grow our insights business. In health benefits, we assess targeted acquisitions through the lens of deepening local density or strengthening our capabilities for specialized populations.
Of course, we balance those investment opportunities with continued capital returns to shareholders. Ultimately, the objective here is to strengthen the enterprise long-term earnings power through disciplined capital allocation.
Okay. Thinking about the integrated model, where does combining health benefits with Carelon create the clearest economic advantage? How do you measure incremental enterprise value versus intercompany eliminations rather than simply shifting earnings between the segments? What evidence shows that the model can succeed with external customers?
We deliver value for our members by connecting capabilities across health benefits and Carelon in ways that are differentiated in the market. We measure the success of our model at the enterprise level through lower total medical costs, improved clinical outcomes, increased member retention, and broader adoption by external customers. This last point is particularly important because it demonstrates that our own capabilities deliver value beyond our health plans. Let me give a couple of examples here. We have demonstrated significant value for employers with integrated medical and pharmacy benefits, with savings of up to $100 per member per month, and that reinforces the value of managing total cost of care. Within CarelonRx, our penetration of our commercial ASO membership is still in the mid-20% range, and we see meaningful opportunity to extend that value to more of our existing customers.
In Medicare Advantage, we have launched a comprehensive D-SNP care management program with CareBridge, and a key pillar of our strategy is to deliver more coordinated care in the home. Our integrated view of our plan design and Carelon's capabilities have allowed us to evaluate investments based on the economics of the entire enterprise rather than just the health plan, and that has created an opportunity to deliver greater value to members while obviously strengthening enterprise returns. In our commercial plans, we have realized significant savings by leveraging Carelon's risk-based oncology solution. That is effectuated effectively by connecting clinical pathways, member navigation, and provider incentives. Our oncology programs are delivering care and reducing avoidable spend, and specifically, our models delivered a 4% reduction in total cost trend for attributed cancer patients, and that translates to over $900 per member per month for those members.
Those are the capabilities that ultimately reinforce the flywheel and our confidence that solutions that we have developed will create durable earnings growth over time.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
